A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'Is the placement of an Amplatzer septal occluder device across a post-infarction ventricular septal defect a suitable alternative for patients not eligible for surgical repair?' Altogether, 31 papers were found using the reported search, of which 17 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We conclude that the insertion of an Amplatzer occluder device in patients with a post-infarction ventricular septal defect (VSD) not amenable to surgical repair can offer benefit in selected patients. Patients with cardiogenic shock frequently have an unfavourable outcome and closure should be considered cautiously. From the literature available, patients have a better outcome if the intervention is delayed by 2 weeks or more possibly due to the maturation of the VSD and recovery of myocardial function. In certain situations, device closure may be complicated by device dislocation or embolization, residual shunting or a tortuous course not amenable to device implantation. In such settings, surgical repair is the only option. In patients who proceed straight to surgical repair with no attempt at percutaneous closure, the overall mortality lies in the region of 43% and similar to percutaneous closure, there is an association observed between those operated within 7 days of the VSD occurrence and those greater than this time. Patients presenting in cardiogenic shock experienced an increased risk of death and if the timing of myocardial infarction to VSD closure could be delayed by 3 weeks, there was a statistically significant reduction in operative mortality. Percutaneous closure of a post-infarction VSD may avoid the requirement for surgical closure. However, in some cases, it provides time to allow the VSD to mature and the patient to stabilize and be optimized acting as a bridge to surgery to offer the best possible outcome for the patient.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION
In patients not eligible for surgical repair of a post-infarction ventricular septal defect (VSD), is the placement of an Amplatzer occluder device a suitable alternative?
CLINICAL SCENARIO
You are called to provide a surgical opinion on a patient who has developed a post-infarction VSD. On the grounds of past medical history and haemodynamic compromise, it is deemed that immediate surgical closure would carry a high risk of mortality. The cardiologist mentions the ability to perform a percutaneous closure of the VSD using an Amplatzer occluder device and you question the value of this management strategy in this setting and resolve to review the literature.
SEARCH STRATEGY

Medline 1950 to March 2013 using Ovid interface
[VSD.tw OR Ventricular adj1 septal adj1 defect$).tw OR exp Heart Septal Defects Ventricular/ OR Post-infarct$ ventricular septal defect$.tw OR Postinfarct$ ventricular septal defect$.mp OR exp Heart Rupture, Post-Infarction/ OR exp Ventricular Septal Rupture/] AND [exp Myocardial Infarction/ OR MI.mp.] AND [Amplatze$ adj1 device).tw OR septal adj1 occlude$ adj1 device$. tw OR transcatheter adj1 closure adj1 device$.tw OR septal adj1 closure adj1 device$.tw OR transcatheter adj1 occlude$ adj1 device$.tw OR VSD adj1 closure adj1 device$.tw OR VSD adj1 occlude$ adj1 device$).tw]. SEARCH OUTCOME Thirty-one papers were found using the reported search. From these, 17 papers were identified that provided the best evidence to answer the question. These are presented in Table 1 .
RESULTS
Thiele et al. [2] reported the largest series of 29 patients with a median age of 72 years. Sixteen patients (55%) were in cardiogenic shock and all had an intra-aortic balloon pump (IABP). Twenty-five patients had successful device placement with 3 patients having unsuccessful device implantation with subsequent death and 1 patient proceeded to surgery following unsuccessful device closure. The median time from VSD occurrence to closure was 1 day and 31% (8 patients) were alive at a median follow-up of 730 days. Patients presenting with cardiogenic shock had a higher 30-day mortality relative to those not in cardiogenic shock (62 vs 9%, respectively; P <0.001).
There was an unquantified residual shunt in 4 patients. Five patients proceeded to surgical closure for either dislocation of the Amplatzer device (3 patients) or residual shunting (2 patients). One of the 3 patients undergoing surgery for device dislocation died. Bialkowski et al. [3] assessed 17 patients with a median age of 66 years. Five patients had an IABP and 11 (65%) survived. The majority of patients were managed 3.5-12 weeks following VSD occurrence. Of these, 5 underwent surgical closure. Of 3 patients managed in the acute phase, 1 died due to pericardial tamponade and 2 proceeded to surgical repair. Of the patients who had a residual shunt, the majority were classified as small and required no further intervention.
Assenza et al. [4] analysed 12 patients with a mean age of 68 years. Cardiogenic shock was present in 7 patients (58%) at the time of closure, which was performed at a median of 19 days following admission. The majority of patients had a trivial-moderate residual shunt. Five patients (42%) died resulting from multiorgan failure. Three patients subsequently proceeded to surgical repair owing to a persisting shunt, one on the same day as the attempted percutaneous closure, one at 1 month and one at 4 months postattempted percutaneous VSD closure.
Marinakis et al. [5] reported on 8 patients with a mean age of 76 years. Shock was present in 50% of patients and 75% had an IABP. Closure was performed in all patients within 1 week except in 2: one was closed at 15 days and the other had the VSD for 6 years. Seven patients had successful device deployment and 6 patients died within 30 days. The only survivor underwent closure at 15 days post-infarction and was alive at 38 months with no residual shunt. A small-to-moderate shunt was present in all and no patient required surgical closure.
Six patients with a mean age of 60 years were reported by Szkutnik et al. [6] . Four patients had successful device deployment. All were closed at 6 weeks or longer, except one performed 2 weeks post-VSD development. A residual shunt was present in all but one. Of the 2 patients who died (33%), one had closure at 6 weeks and one had immediate surgery following inability to cross the defect. One other patient required surgical closure performed with success at 2 weeks.
Martinez et al. [7] analysed 4 patients aged between 51 and 88 years. Three patients survived with one requiring the deployment of a second device 4 months later due to a residual shunt. The timing of the procedures was not provided except for the patient who had closure performed 3 days post-VSD occurrence resulting in death 5 days later. No subsequent surgical closure was necessary.
Three patients aged between 66 and 75 years were studied by Ahmed et al. [8] . Two of the three Amplatzer devices were successfully deployed with trivial shunts documented. Two patients survived, both of whom had treatment 50 days after the infarct and none required surgical closure.
Parsi et al. [9] reported on 2 patients aged 75 and 78 years with successful device deployment. One patient treated 14 days postinfarction was well at 6 months; one patient treated at 10 days post-infarction died due to cardiogenic shock.
There were nine case reports of patients with a post-infarction VSD who underwent primary transcatheter closure with an Amplatzer device [10] [11] [12] [13] [14] [15] [16] [17] [18] . Successful device deployment was reported in all but one in whom the long and tortuous VSD course would not allow closure leading to death owing to multiorgan failure and another 3 patients died due to renal failure; gradual left ventricular impairment and cardiogenic shock. All but one patient had evidence of a residual shunt. Five patients were treated in the acute phase of which 3 survived. Three patients were managed in the chronic phase (14 days or more) of which 2 survived. No patient required surgical repair.
Arnaoutakis et al. [19] reported on 2876 patients with a postinfarction VSD who proceeded straight to surgical repair. The overall mortality rate in this large cohort was 42.9% and it was found that surgical repair within 7 days was met with a higher operative mortality rate compared with delayed intervention after 7 days (54.1 vs 18.4%, respectively). Similar to percutaneous transcatheter closure, surgical closure in the presence of cardiogenic shock was found to be independently associated with a greater odds ratio of operative death and if the timing from MI to VSD repair was more than 21 days, there was a lower odds of operative mortality (P <0.01).
CLINICAL BOTTOM LINE
The insertion of an Amplatzer occluder device in patients with a post-infarction VSD can offer benefit in selected patients. Patients with cardiogenic shock frequently have an unfavourable outcome and closure should be considered cautiously. From the literature available, patients have a better outcome if the intervention is delayed by 2 weeks or more possibly due to the maturation of the VSD and recovery of myocardial function. The mortality rate associated with the repair of a post-infarction VSD is one of the highest of all cardiac surgical procedures and the placement of an Amplatzer septal occluder device may allow complete closure of the defect. However, it can also act as a bridge to surgical repair following a period of stabilization and patient optimization to offer the best possible outcome in this frequently fatal condition.
